Results mark first evidence of potential clinical benefit of antisense oligonucleotide therapy in a pulmonary disease Encouraging safety profile with no identified safety signals to date Improvement in lung function observed in up to 70% of participants treated with SPL84 The readout validates SpliSense’ platform, supporting advancement of the Company’s additional pulmonary programs, for muco-obstructive … …
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is … …
JERUSALEM, July 25, 2024 /PRNewswire/ — Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor resistance, today announced a global, exclusive license agreement with Immunome Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies. Under the terms of the license, Immunome received exclusive rights to … …
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new … …
MISGAV, Israel, June 24, 2024 /PRNewswire/ — Biond Biologics Ltd. (“Biond” or the “Company”), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of biologics, today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody. The first patient was administered BND-35 as a monotherapy … …
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense oligonucleotide (ASO) … …
– Funding secured from CF Foundation and current investors for SPL84 Phase 2 study – – Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ — SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including … …
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares … …
(RTTNews) – MediWound Ltd. (MDWD) Monday reported positive results from head-to-head comparison analyses of the company’s lead asset EscharEx for the treatment of chronic wounds to SANTYL ointment. SANTYL was approved by the FDA for debriding chronic dermal ulcers. Results from the secondary analyses of the Phase II ChronEx study showed that EscharEx was superior … …
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. … …